Zenas BioPharma, Inc. Common Stock
Follow $ZBIO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ZBIO by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ZBIO moving today?
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ZBIO overview
Related filings and maps
Congress activity in ZBIO
No receipt-qualified Congressional disclosure is present for ZBIO in the cached public ledger.
ZBIO contract awards, year to date.
Public federal awards linked to this ticker.
ZBIO lobbying filings, year to date.
Registered lobbying filings matched to Zenas BioPharma, Inc. Common Stock.